Quick Answer
NewAmsterdam Pharma Co N.V. reported Operating Income of -$225.68 million for fiscal year 2025.
NewAmsterdam Pharma Co N.V. Operating Income — Annual History
| Fiscal Year | Operating Income | YoY Change |
|---|---|---|
| 2025 | -$225.68M | -28.0% |
| 2024 | -$176.29M | +3.6% |
| 2023 | -$182.97M | -5043.9% |
| 2022 | -$3.56M | +89.8% |
| 2021 | -$34.98M | — |
Quarterly Operating Income
| Quarter Ending | Operating Income | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$55.14M | -120.5% | -54.7% |
| June 30, 2025 | -$35.63M | +32.2% | +48.3% |
| March 31, 2025 | -$68.92M | -24.2% | -175.7% |
| September 30, 2024 | -$25.00M | +49.5% | +52.4% |
| June 30, 2024 | -$52.58M | -23.8% | +5.2% |
| March 31, 2024 | -$55.48M | -39.2% | -12.0% |
| September 30, 2023 | -$49.56M | — | -16.7% |
| June 30, 2023 | -$42.48M | — | -6.6% |
- NewAmsterdam Pharma Co N.V. showed a decrease of -28.0% in Operating Income compared to the prior fiscal year.
- Over the 2021–2025 period, NewAmsterdam Pharma Co N.V.’s operating income has declined by 545.2% (from -$34.98 million to -$225.68 million).
- The most recent figure is from NewAmsterdam Pharma Co N.V.’s fiscal year 2025 report (Form 10-K), filed with the SEC on February 18, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: